Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
January 04, 2022 07:00 ET
|
Advicenne
Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region Advicenne will receive a transfer price and royalties for an amount markedly higher than 50%...
Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA
December 20, 2021 07:00 ET
|
Advicenne
Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA ...
Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe
December 07, 2021 07:00 ET
|
Advicenne
Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe First round of pricing negotiations completed in the United KingdomTwinPharma and ExCEEd Orphan to...
Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA
July 02, 2021 01:00 ET
|
Advicenne
Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA ...
Advicenne provides an update on its activities following its Annual General Meeting
June 15, 2021 12:17 ET
|
Advicenne
Advicenne provides an update on its activities followingits Annual General Meeting Introducing Advicenne 2.0, the Company’s strategy to unlock valuePoised to partner Sibnayal in dRTA in Europe...
Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)
May 17, 2021 12:03 ET
|
Advicenne
Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA) FDA accepts amended protocol...
Advicenne reçoit un avis positif de la FDA sur la procédure d'approbation et l’Agence accepte le protocole modifié de l'étude de phase III pour son traitement de l'acidose tubulaire rénale distale (ATRd)
May 17, 2021 12:00 ET
|
Advicenne
Advicenne reçoit un avis positif de la FDA sur la procédure d'approbation et l’Agence accepte le protocole modifié de l'étude de phase III pour son traitement de l'acidose tubulaire rénale distale...